The 2025 AIM-HI Women’s Venture Competition is now open to women-led oncology companies worldwide! This online application is comprised of three parts: general information, a presentation summarizing a business plan, and a brief video delivered in easy-to-understand language for a general audience. Each component must be completed and submitted before the application deadline, Saturday, March 15, 2025 at 11:55 PM EST.

Women-led oncology companies seeking pre-seed, seed, and Series A investments are eligible to apply. The company must have a woman in senior leadership, who has an equity stake – could be Founder or C-level executive. If the company wins, it must have technology ownership in place to be eligible to receive investment funding from AIM-HI and co-investors.

All submitted applications will be reviewed and screened by our Selection Committee based on the quality of applications. 6-8 semi-finalists will be chosen around late April and invited to compete in front of a Judging Committee in June to select finalists who will be recognized and awarded honorariums and certificates.

An Investment Committee will conduct detailed due diligence research on the finalists to determine whether an investment will be made based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will receive up to $1 million in investment from AIM-HI and co-investors.

Our three-part Selection, Judging, and Investment Committees consist of world-class life sciences industry professionals, business leaders, and investors.

If the online application is not appearing in your browser below, please e-mail AIM-HI Program Manager Ella Ye at eye@aim-hiaccelerator.org to request a PDF version, and she will respond within 24 hours.